New England Journal of Medicine· 2012Q1

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni, Ian E. Krop et al.

3,802citations
Q1SCImago
2012year

Short summary

Trastuzumab emtansine (T-DM1) significantly improved progression-free survival (9.6 vs. 6.4 months) and overall survival (30.9 vs. 25.1 months) compared to lapatinib plus capecitabine in patients with previously treated HER2-positive advanced breast cancer.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine